Promega Launches Paradyme™ 27GY STR System, Minimizing Stutter Artifacts in Forensic DNA Analysis
29.9.2026 13:00:00 CEST | Business Wire | Press release
Reduced-Stutter Polymerase technology delivers clearer electropherograms for faster and more accurate mixture analysis
Promega Corporation has launched Paradyme™ 27GY STR System, the first commercially available short tandem repeat (STR) analysis kit to include the company’s Reduced-Stutter Polymerase (RSP). This novel enzyme, engineered by Promega, significantly reduces the most common type of confounding artifact in forensic DNA analysis. The result is an 8-fold reduction in stutter signal intensity, producing clearer electropherograms, improving confidence in number-of-contributors (NoC) determination, and enhancing detection of minor contributors in mixed samples. Ultimately, this leads to faster mixture interpretation with higher confidence and the ability to interpret more complex mixtures, helping labs solve more cases and reduce backlogs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918993802/en/
“This is the first forensic STR analysis kit to virtually eliminate stutter at its source,” says Tim Kupferschmid, Sr. Director of Genetic Identity, Promega Corporation. “By simplifying mixture deconvolution, Paradyme™ 27GY STR System will fundamentally change what analysts can deliver to investigators.”
The kit is designed for use with Spectrum CE System and Spectrum Compact CE System. Promega is the first manufacturer to develop and launch a capillary electrophoresis instrument capable of 8-dye STR analysis.
Reduced Stutter in Forensic DNA Analysis
Stutter has been a major challenge of forensic DNA analysis for decades. When DNA is amplified using Taq polymerase, the enzyme occasionally slips across repeated sequences, resulting in a new fragment that is shorter than the original. When the sample is analyzed by capillary electrophoresis, the resulting electropherogram will show an extra peak that is one repeat shorter, and sometimes one repeat longer, than the true peak. These extra peaks create challenges for analysis when a sample potentially contains DNA from multiple contributors. It is difficult to determine whether a peak represents stutter or an allele from a minor contributor.
The enzyme included in Paradyme™ 27GY STR System is engineered to minimize “slippage” during amplification of repetitive DNA sequences common in forensic DNA analysis. The enzyme reduces stutter signal intensity by an average of 8-fold relative to current systems, often rendering it undetectable from instrument baseline noise. This minimizes a significant source of uncertainty in forensic casework. As a result, labs are able to provide conclusive results for complex mixtures, generate more accurate profiles for casework and databases, and decrease their turnaround time for sample analysis.
Promega first unveiled the novel engineered enzyme at the International Symposium on Human Identification in 2024.
Advantages of Paradyme™ 27GY STR System
Paradyme™ 27GY STR System is an 8-dye multiplex that includes 23 autosomal STR loci, Amelogenin and key Y-STR loci, supporting CODIS core loci requirements and the expanded CODIS framework used by crime laboratories in the United States and internationally.
System benefits include:
- Average of 8-fold reduction in stutter signal intensity, producing clearer profiles at amplification
- Fewer data edits, reducing time spent on analysis
- Reduced stutter and Y-STR loci improve NoC determination accuracy
- Higher interpretation confidence with more complex mixtures, reducing analyst fatigue and secondary technical review effort
- Increased minor contributor detection in mixtures
- More loci amplified from degraded samples using shortened-amplicon 8-dye multiplex
- Quality Indicator peaks that support more informed assessment of amplification success and sample quality troubleshooting
Promega offers extensive support to forensic organizations interested in adopting Paradyme™ 27GY STR System. Laboratories can contact a local Promega representative about in-house evaluation and comparison against current chemistry. For implementation support, Promega offers forensic experts to support on-site optimization, customized validation, and hands-on training for chemistry and instrumentation with over 200 forensic customer validation projects completed globally.
For more information about Paradyme™ 27GY STR System, visit www.promega.com/ParadymePR.
About Promega Corporation
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at promega.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260918993802/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Heaviside Industries Awarded $99M IDIQ Contract to Provide MOTH Spectrum Analyzers to U.S. Army29.9.2026 14:00:00 CEST | Press release
MOTH’s low size, weight, power, and cost enable distributed spectrum awareness in support of U.S. Army EMSO priorities Heaviside Industries, a builder of multi-domain precision munitions platforms, announced it has been awarded a $99 million firm-fixed-price, indefinite delivery, indefinite quantity (IDIQ) contract by the U.S. Army to deliver its MOTH radio frequency (RF) spectrum analyzers in support of the Army’s electromagnetic spectrum operations (EMSO) priorities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929455358/en/ The five-year contract was awarded by U.S. Army Contracting Command at Aberdeen Proving Ground, Maryland and includes system procurement, fielding, upgrades, and sustainment. As unmanned systems proliferate and adversaries increasingly exploit the electromagnetic spectrum, the Army requires EMSO capabilities that are scalable, adaptable, and rapidly fieldable to maintain an advantage in the spectr
Royal Yacht International Represents Buyer in Landmark 132M Lürssen as Founder Predicts: “The Billion-dollar Yacht Is Coming”29.9.2026 14:00:00 CEST | Press release
The Monaco-Miami advisory firm is building a different model for ultra-high-value yacht acquisitions, combining access, negotiation, technical expertise and selective, founder-led representation. Royal Yacht International has announced PROJECT M, a fully custom 132-metre Lürssensuperyacht exceeding 6,000 GT. But for Royal Yacht International Founder and CEO Tommaso Chiabra, the project is less about size than what it represents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928365204/en/ Project M At the very top of the luxury market, the world’s most exceptional yachts are becoming increasingly difficult to reproduce. Only a small number of shipyards can execute projects of this scale. Construction takes years. Specialist capacity is finite. Build slots are scarce. And replacement cost can change dramatically between contract signing and delivery. “People look at purchase price. Sophisticated owners look at replacement
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America29.9.2026 14:00:00 CEST | Press release
This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region. Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. Under the terms of the agreement, Knight will be responsible for seeking the necessary regulatory approvals and commercialising mogamulizumab for mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of CTCL, a rare non-Hodgkin’s lymphoma, in Argentina, Brazil, Colombia and Mexico. Knight will hold exclusive distributi
Create Apps Championship Winners Highlight Dubai’s Strength as a Base for Scaling Digital Businesses29.9.2026 13:49:00 CEST | Press release
Winners of past editions of Dubai Chamber of Digital Economy’s Create Apps Championship have highlighted how Dubai is helping entrepreneurs transform promising ideas into scalable digital ventures, with the championship playing a key role in supporting their growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929068961/en/ During Create Apps Championship 2025 (Photo: AETOSWire) Launched in 2023 as part of the ‘Create Apps in Dubai’ initiative, the championship supports participants through specialised training, mentorship, connections with investors and partners, and funding to develop and launch winning apps. Mariam Mohammed Almarri, Co-Founder of Boom, said: “A major milestone in our journey was participating in the Create Apps Championship, where Boom was recognised as ‘Dubai’s App of the Year 2025’ and ‘Most Impactful App’. This recognition enabled us to build Boom and transport it from an idea into a real product.
SLB OneSubsea Awarded Major Subsea Systems Contract for Rovuma Basin Development29.9.2026 13:46:00 CEST | Press release
Agreement with ExxonMobil Moçambique, Limitada supports development of LNG deepwater resources in Mozambique Global energy technology company SLB (NYSE: SLB) today announced that its OneSubsea™ joint venture has been awarded a contract by ExxonMobil Moçambique, Limitada, on behalf of its Area 4 partners, (ENH, CNPC, ENI, KOGAS and XRG), to deliver subsea production systems for the first phase of the offshore Rovuma LNG project in Mozambique. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916187961/en/ SLB OneSubsea™ joint venture has been awarded a contract by ExxonMobil Moçambique, Limitada, on behalf of its Area 4 partners, (ENH, CNPC, ENI, KOGAS and XRG), to deliver subsea production systems for the first phase of the offshore Rovuma LNG project in Mozambique. The contract scope includes the delivery of subsea trees, manifolds, umbilicals and associated control systems designed to support efficient production from the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom